MP55-10 EPIGENETIC REGULATION OF THE 3P22 TUMOR SUPPRESSOR DLEC1 IN HUMAN PROSTATE CANCER ASSOCIATED WITH ITS PROGNOSIS

Lian Zhang,Yu Fan
DOI: https://doi.org/10.1016/j.juro.2015.02.2053
IF: 7.6
2015-01-01
The Journal of Urology
Abstract:You have accessJournal of UrologyProstate Cancer: Basic Research III1 Apr 2015MP55-10 EPIGENETIC REGULATION OF THE 3P22 TUMOR SUPPRESSOR DLEC1 IN HUMAN PROSTATE CANCER ASSOCIATED WITH ITS PROGNOSIS Lian Zhang, Yu Fan, Lili Li, Zhaohui Wang, Qian Zhang, Qian Tao, and Jie Jin Lian ZhangLian Zhang More articles by this author , Yu FanYu Fan More articles by this author , Lili LiLili Li More articles by this author , Zhaohui WangZhaohui Wang More articles by this author , Qian ZhangQian Zhang More articles by this author , Qian TaoQian Tao More articles by this author , and Jie JinJie Jin More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.2053AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Deleted in lung and esophageal cancer 1 (DLEC1), located on 3p22-p21.3, is involved in carcinogenesis of multiple cancers, but its role in prostate cancer (PrCa) remains unclear. Here, we reported the epigenetic alterations of DLEC1 and its biological function in prostate carcinogenesis, and also studied the potentially useful application of DLEC1 methylation in prostate cancer diagnosis. METHODS We detected the expression and methylation of DLEC1, and assessed its tumor suppressive functions in PrCa cell lines (PC3, DU145, and LNCap). DLEC1 methylation was further examined by methylation-specific PCR in tissue DNA from 110 prostate carcinomas and 26 benign prostatic hyperplasias (BPH). We also detected the methylation of DLEC1 promoter in the urine sediments from the pre-biopsy patients with elevated PSA. All samples were harvested after obtaining patients' written content and defined by two urological pathology physicians. RESULTS It's observed that DLEC1 was highly expressed in human normal prostatic epithelium cell line (RWPE-1), benign prostatic hyperplasia cell line (BPH-1) and normal prostate tissue, but frequently downregulated by promoter methylation in PrCa cell lines. PrCa tissues expressed lower level of DLEC1 than their adjacent non-malignant tissues. DLEC1 was methylated in 76 out of 110 primary tumors, but rarely in BPH tissues. This methylation was associated with higher PSA levels (p=0.016), higher gleason scores (p=0.015), and more advanced tumor stages (p=0.003). Furthermore, DLEC1 methyation was detected in 35 out of 95 urine sediments from confirmed PrCa patients, 20 out of 81 urine sediments from the unconfirmed PrCa patient with elevated PSA. Pharmacologic demethylation treatment restored DLEC1 expression. Re-expression of DLEC1 inhibited colony formation and migration abilities of PrCa cells, through promoting apoptosis. Moreover, overexpression of DLEC1 could inhibit the activities of NF-κB both in PrCa cells and HEK293 cells. CONCLUSIONS Taken together, our data suggests that DLEC1 as a functional tumor suppressor may be frequently methylated in PrCa and associates with tumor progression. The DLEC1 methylation detection in urine sediments indicates that it might serve as a potential noninvasive neo-biomarker for prostate cancer early diagnosis. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e676 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.Metrics Author Information Lian Zhang More articles by this author Yu Fan More articles by this author Lili Li More articles by this author Zhaohui Wang More articles by this author Qian Zhang More articles by this author Qian Tao More articles by this author Jie Jin More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...
What problem does this paper attempt to address?